Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems

Modern Pathology

Volumn 27, Issue 5, 2014, Pages 681-689

  Fu, Bin ^a,b   Jaso, Jesse M ^a   Sargent, Rachel L ^a   Goswami, Maitrayee ^a   Verstovsek, Srdan ^a   Medeiros, L Jeffrey ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

bone marrow fibrosis; cytogenetics; JAK2 V617F; myelodysplastic syndromes; survival

Indexed keywords

CEBPA PROTEIN; FLT3 LIGAND; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE 2; KIT PROTEIN; LENALIDOMIDE; MPL PROTEIN; NUCLEOPHOSMIN; RAS PROTEIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; EVENT FREE SURVIVAL; FEMALE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT RESPONSE; VERY ELDERLY; BONE MARROW; BONE MARROW EXAMINATION; FIBROSIS; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BONE MARROW EXAMINATION; DISEASE PROGRESSION; FEMALE; FIBROSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84899898005     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.187     Document Type: Article

References (28)

1. Verhoef GE, De Wolf-Peeters C, Ferrant A, et al.Myelodysplastic syndromes with bone marrow fibrosis:a myelodysplastic disorder with proliferativefeatures. Ann Hematol 1991;63:235-241.
2. Lambertenghi-Deliliers G, Orazi A, Luksch R, et al.Myelodysplastic syndrome with increased marrowfibrosis: a distinct clinico-pathological entity. Br JHaematol 1991;78:161-166.
3. Vardiman JW, Thiele J, Arber DA, et al. The 2008revision of the World Health Organization (WHO)classification of myeloid neoplasms and acute leukemia:rationale and important changes. Blood2009;114:937-951.
4. Buesche G, Teoman H, Wilczak W, et al. Marrowfibrosis predicts early fatal marrow failure in patientswith myelodysplastic syndromes. Leukemia2008;22:313-322.
5. Della Porta MG, Malcovati L, Boveri E, et al. Clinicalrelevance of bone marrow fibrosis and CD34-positivecell clusters in primary myelodysplastic syndromes.J Clin Oncol 2009;27:754-762.
6. Lambertenghi-Deliliers G, Annaloro C, Oriani A, et al.Prognostic relevance of histological findings on bonemarrow biopsy in myelodysplastic syndromes. AnnHematol 1993;66:85-91.
7. Maschek H, Georgii A, Kaloutsi V, et al. Myelofibrosisin primary myelodysplastic syndromes: a retrospectivestudy of 352 patients. Eur J Haematol 1992;48:208-214.
8. Maschek H, Gutzmer R, Choritz H, et al. Lifeexpectancy in primary myelodysplastic syndromes: aprognostic score based upon histopathology from bonemarrow biopsies of 569 patients. Eur J Haematol1994;53:280-287.
9. Gianelli U, Vener C, Bossi A, et al. The EuropeanConsensus on grading of bone marrow fibrosis allows abetter prognostication of patients with primary myelofibrosis.Mod Pathol 2012;25:1193-1202.
10. Greenberg PL, Tuechler H, Schanz J, et al. Revisedinternational prognostic scoring system for myelodysplasticsyndromes. Blood 2012;120:2454-2465.
11. Schanz J, Tuchler H, Sole F, et al. New comprehensivecytogenetic scoring system for primary myelodysplasticsyndromes (MDS) and oligoblastic acute myeloidleukemia after MDS derived from an internationaldatabase merge. J Clin Oncol 2012;30:820-829.
12. Thiele J, Kvasnicka HM, Facchetti F, et al. Europeanconsensus on grading bone marrow fibrosis andassessment of cellularity. Haematologica 2005;90:1128-1132.
13. Khoury JD, Sen F, Abruzzo LV, et al. Cytogeneticfindings in blastoid mantle cell lymphoma. HumPathol 2003;34:1022-1029.
14. ChenW, Konoplev S, Medeiros LJ, et al. Cuplike nuclei(prominent nuclear invaginations) in acute myeloidleukemia are highly associated with FLT3 internaltandem duplication and NPM1 mutation. Cancer2009;115:5481-5489.
15. Millecker L, Lennon PA, Verstovsek S, et al. Distinctpatterns of cytogenetic and clinical progression inchronic myeloproliferative neoplasms with or withoutJAK2 or MPL mutations. Cancer Genet Cytogenet2010;197:1-7.16.
16. Gustafson SA, Lin P, Chen SS, et al. Therapy-relatedacute myeloid leukemia with t(8;21) (q22;q22) sharesmany features with de novo acute myeloid leukemiawith t(8;21)(q22;q22) but does not have a favorableoutcome. Am J Clin Pathol 2009;131:647-655.
17. Tefferi A. Pathogenesis of myelofibrosis with myeloidmetaplasia. J Clin Oncol 2005;23:8520-8530.
18. Buhr T, Busche G, Choritz H, et al. Evolution ofmyelofibrosis in chronic idiopathic myelofibrosis asevidenced in sequential bone marrow biopsy specimens.Am J Clin Pathol 2003;119:152-158.
19. Kroger N, Zabelina T, van Biezen A, et al. Allogeneicstem cell transplantation for myelodysplastic syndromeswith bone marrow fibrosis. Haematologica2011;96:291-297.
20. Kroger N, Kvasnicka M, Thiele J. Replacement ofhematopoietic system by allogeneic stem cell transplantationin myelofibrosis patients induces rapidregression of bone marrow fibrosis. FibrogenesisTissue Repair 2012;5(Suppl 1):S25.
21. Ohyashiki K, Aota Y, Akahane D, et al. The JAK2V617F tyrosine kinase mutation in myelodysplasticsyndromes (MDS) developing myelofibrosis indicatesthe myeloproliferative nature in a subset of MDSpatients. Leukemia 2005;19:2359-2360.
22. Olsen RJ, Dunphy CH, O'Malley DP, et al. Theimplication of identifying JAK2 ( V617F ) in myeloproliferativeneoplasms and myelodysplastic syndromeswith bone marrow fibrosis. J Hematop 2008;1:111-117.
23. Yip SF, So CC, Chan AY, et al. The lack of associationbetween JAK2 V617F mutation and myelodysplasticsyndrome with or without myelofibrosis. Leukemia2006;20:1165.
24. Kremer M, Horn T, Dechow T, et al. The JAK2 V617Fmutation occurs frequently in myelodysplastic/myeloproliferativediseases, but is absent in true myelodysplasticsyndromes with fibrosis. Leukemia 2006;20:1315-1316.
25. Fu B, Ok CY, Goswami M, et al. The clinicalimportance of moderate/severe bone marrow fibrosisin patients with therapy-related myelodysplastic syndromes.Ann Hematol 2013;92:1335-1343.
26. Valent P, Orazi A, Busche G, et al. Standards andimpact of hematopathology in myelodysplastic syndromes(MDS). Oncotarget 2010;1:483-496.
27. Sokol L, Caceres G, Rocha K, et al. JAK2(V617F)mutation in myelodysplastic syndrome (MDS) withdel(5q) arises in genetically discordant clones. LeukRes 2010;34:821-823.
28. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essentialthrombocythemia and agnogenic myeloid metaplasia:an Olmsted County Study, 1976-1995. Am J Hematol1999;61:10-15.